Therapeutic targets in heart failure: Refocusing on the myocardial interstitium

Journal of the American College of Cardiology

Volumn 63, Issue 21, 2014, Pages 2188-2198

  Schelbert, Erik B ^a   Fonarow, Gregg C ^b   Bonow, Robert O ^c   Butler, Javed ^d   Gheorghiade, Mihai ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

extracellular matrix; extracellular volume fraction; heart failure; myocardial fibrosis

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN; GADOLINIUM; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; FINERENONE; GALECTIN 3; MICRORNA; MINERALOCORTICOID ANTAGONIST; NESIRITIDE; OMAPATRILAT; PIRFENIDONE; RELAXIN; SERELAXIN; SIMTUZUMAB;

ARTICLE; CARDIAC IMAGING; CELL EXPANSION; CELL FUNCTION; CELL VOLUME; CONTRAST ENHANCEMENT; EXTRACELLULAR MATRIX; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; INCIDENCE; INTERSTITIUM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; CARDIOVASCULAR MAGNETIC RESONANCE; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; EXTRACELLULAR SPACE; FIBROBLAST; FIBROSING ALVEOLITIS; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HYPERTENSION; INTERSTITIAL HEART DISEASE; MYOCARDIAL INTERSTITIUM;

EXTRACELLULAR MATRIX; EXTRACELLULAR VOLUME FRACTION; HEART FAILURE; MYOCARDIAL FIBROSIS;

ANIMALS; CARDIOTONIC AGENTS; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC;

EID: 84901611008     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.01.068     Document Type: Review

References (139)

1. M. Gheorghiade, W.T. Abraham, and N.M. Albert et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure JAMA 296 2006 2217 2226
2. P.S. Pang, M. Komajda, and M. Gheorghiade The current and future management of acute heart failure syndromes Eur Heart J 31 2010 784 793
3. M. Gheorghiade, and E. Braunwald Hospitalizations for heart failure in the United States-a sign of hope JAMA 306 2011 1705 1706
4. M. Gheorghiade, P.S. Pang, and C.M. O'Connor et al. Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase Am Heart J 161 2011 224 232
5. M. Vaduganathan, S.J. Greene, A.P. Ambrosy, M. Gheorghiade, and J. Butler The disconnect between phase II and phase III trials of drugs for heart failure Nat Rev Cardiol 10 2013 85 97
6. G.C. Fonarow, and E.D. Peterson Heart failure performance measures and outcomes: real or illusory gains JAMA 302 2009 792 794
7. M. Gheorghiade, and E.D. Peterson Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes JAMA 305 2011 2456 2457
8. R.O. Bonow, T.G. Ganiats, and C.T. Beam et al. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement J Am Coll Cardiol 59 2012 1812 1832
9. M. Gheorghiade, and E. Braunwald A proposed model for initial assessment and management of acute heart failure syndromes JAMA 305 2011 1702 1703
10. M. Gheorghiade, M. Vaduganathan, G.C. Fonarow, and R.O. Bonow Rehospitalization for heart failure: problems and perspectives J Am Coll Cardiol 61 2013 391 403
11. K.T. Weber, and C.G. Brilla Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system Circulation 83 1991 1849 1865
12. B. Swynghedauw Molecular mechanisms of myocardial remodeling Physiol Rev 79 1999 215 262
13. D.L. Mann, P.M. Barger, and D. Burkhoff Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol 60 2012 2465 2472
14. N. Mewton, C.Y. Liu, P. Croisille, D. Bluemke, and J.A. Lima Assessment of myocardial fibrosis with cardiovascular magnetic resonance J Am Coll Cardiol 57 2011 891 903
15. T.C. Wong, K. Piehler, and I.A. Kang et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission Eur Heart J 35 2014 657 664
16. T.C. Wong, K. Piehler, and C.G. Meier et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality Circulation 126 2012 1206 1216
17. K.T. Weber Cardiac interstitium in health and disease: the fibrillar collagen network J Am Coll Cardiol 13 1989 1637 1652
18. C.G. Brilla, R.C. Funck, and H. Rupp Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease Circulation 102 2000 1388 1393
19. B. Schwartzkopff, M. Brehm, M. Mundhenke, and B.E. Strauer Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease Hypertension 36 2000 220 225
20. J. Diez, R. Querejeta, B. Lopez, A. Gonzalez, M. Larman, and J.L. Martinez Ubago Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients Circulation 105 2002 2512 2517
21. H. Izawa, T. Murohara, and K. Nagata et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study Circulation 112 2005 2940 2945
22. P. Kong, P. Christia, and N.G. Frangogiannis The pathogenesis of cardiac fibrosis Cell Mol Life Sci 72 2014 549 574
23. A. Patel, S. MacMahon, and J. Chalmers et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 2007 829 840
24. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
25. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
26. M.A. Pfeffer, E. Braunwald, L.A. Moye for the SAVE Investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial N Engl J Med 327 1992 669 677
27. B. Pitt, F. Zannad, and W.J. Remme et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
28. B. Pitt, W. Remme, and F. Zannad et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
29. F. Zannad, J.J. McMurray, and H. Krum et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
30. C.B. Granger, J.J. McMurray, and S. Yusuf et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
31. F. Zannad, F. Alla, B. Dousset, A. Perez, and B. Pitt Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators Circulation 102 2000 2700 2706
32. M. Metra, G. Cotter, and B.A. Davison et al. Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program J Am Coll Cardiol 61 2013 196 206
33. C.S. Samuel, T.D. Hewitson, Y. Zhang, and D.J. Kelly Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy Endocrinology 149 2008 3286 3293
34. E.D. Lekgabe, H. Kiriazis, and C. Zhao et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats Hypertension 46 2005 412 418
35. J.M. McLenachan, and H.J. Dargie Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis Am J Hypertens 3 1990 735 740
36. T. Kawara, R. Derksen, and J.R. de Groot et al. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis Circulation 104 2001 3069 3075
37. K.P. Anderson, R. Walker, P. Urie, P.R. Ershler, R.L. Lux, and S.V. Karwandee Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy J Clin Invest 92 1993 122 140
38. B.K. Tamarappoo, B.T. John, and K. Reinier et al. Vulnerable myocardial interstitium in patients with isolated left ventricular hypertrophy and sudden cardiac death: a postmortem histological evaluation J Am Heart Assoc 1 2012 e001511
39. K. Khavandi, A. Khavandi, and O. Asghar et al. Diabetic cardiomyopathy-a distinct disease? Best Pract Res Clin Endocrinol Metab 23 2009 347 360
40. J. Asbun, and F.J. Villarreal The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy J Am Coll Cardiol 47 2006 693 700
41. S. Goser, M. Andrassy, and S.J. Buss et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium Circulation 114 2006 1693 1702
42. M. Naghavi, P. Libby, and E. Falk et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I Circulation 108 2003 1664 1672
43. K.H. van Hoeven, and S.M. Factor A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease Circulation 82 1990 848 855
44. T.A. Wynn, and T.R. Ramalingam Mechanisms of fibrosis: therapeutic translation for fibrotic disease Nat Med 18 2012 1028 1040
45. B.I. Jugdutt The continuing saga of aging and heart failure Heart Fail Rev 17 2012 529 530
46. C.-Y. Liu, Y.C. Liu, and C. Wu et al. Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis) J Am Coll Cardiol 62 2013 1280 1287
47. J.C. Moon, T.A. Treibel, and E.B. Schelbert T1 mapping for diffuse myocardial fibrosis: a key biomarker in cardiac disease? J Am Coll Cardiol 62 2013 1288 1289
48. T. Thum, C. Gross, and J. Fiedler et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts Nature 456 2008 980 984
49. D.M. Sado, A.S. Flett, and S.M. Banypersad et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease Heart 98 2012 1436 1441
50. P. Kellman, J.R. Wilson, and H. Xue et al. Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience J Cardiovasc Magn Reson 14 2012 64
51. S.M. Banypersad, D.M. Sado, and A.S. Flett et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study Circ Cardiovasc Imaging 6 2012 34 39
52. S.M. Banypersad, J.C. Moon, C. Whelan, P.N. Hawkins, and A.D. Wechalekar Updates in cardiac amyloidosis: a review J Am Heart Assoc 1 2012 e000364
53. G. Palladini, C. Campana, and C. Klersy et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis Circulation 107 2003 2440 2445
54. A. Dispenzieri, M.A. Gertz, and R.A. Kyle et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis J Clin Oncol 22 2004 3751 3757
55. A. Dispenzieri, M.A. Gertz, and R.A. Kyle et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood 104 2004 1881 1887
56. A. Dispenzieri, R.A. Kyle, and M.A. Gertz et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins Lancet 361 2003 1787 1789
57. J. Kim, A.D. Eckhart, S. Eguchi, and W.J. Koch Beta-adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases J Biol Chem 277 2002 32116 32123
58. S.K. White, D.M. Sado, A.S. Flett, and J.C. Moon Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging Heart 98 2012 773 779
59. D.M. Sado, A.S. Flett, and J.C. Moon Novel imaging techniques for diffuse myocardial fibrosis Future Cardiol 7 2011 643 650
60. M. Tanaka, H. Fujiwara, T. Onodera, D.J. Wu, Y. Hamashima, and C. Kawai Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy Br Heart J 55 1986 575 581
61. C.A. Beltrami, N. Finato, and M. Rocco et al. The cellular basis of dilated cardiomyopathy in humans J Mol Cell Cardiol 27 1995 291 305
62. M.A. Rossi Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans J Hypertens 16 1998 1031 1041
63. P. Camelliti, T.K. Borg, and P. Kohl Structural and functional characterisation of cardiac fibroblasts Cardiovasc Res 65 2005 40 51
64. A.J. Woodiwiss, O.J. Tsotetsi, and S. Sprott et al. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction Circulation 103 2001 155 160
65. B. Lopez, R. Querejeta, A. Gonzalez, M. Larman, and J. Diez Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase Hypertension 60 2012 677 683
66. C.G. Brilla, B. Maisch, G. Zhou, and K.T. Weber Hormonal regulation of cardiac fibroblast function Eur Heart J 16 Suppl C 1995 45 50
67. E.B. Schelbert, S.M. Testa, and C.G. Meier et al. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus J Cardiovasc Magn Reson 13 2011 16
68. C. Jellis, J. Martin, J. Narula, and T.H. Marwick Assessment of nonischemic myocardial fibrosis J Am Coll Cardiol 56 2010 89 97
69. N. Kawel, M. Nacif, and A. Zavodni et al. T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA J Cardiovasc Magn Reson 14 2012 26
70. M. Salerno, R. Janardhanan, and R.S. Jiji et al. Comparison of methods for determining the partition coefficient of gadolinium in the myocardium using T1 mapping J Magn Reson Imaging 38 2013 217 224
71. M. Ugander, A.J. Oki, and L.Y. Hsu et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology Eur Heart J 33 2012 1268 1278
72. L. Iles, H. Pfluger, and A. Phrommintikul et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping J Am Coll Cardiol 52 2008 1574 1580
73. C.T. Sibley, R.A. Noureldin, and N. Gai et al. T1 mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy Radiology 265 2012 724 732
74. J.C. Moon, D.R. Messroghli, and P. Kellman et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement J Cardiovasc Magn Reson 15 2013 92
75. A.S. Flett, M.P. Hayward, and M.T. Ashworth et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans Circulation 122 2010 138 144
76. C.A. Miller, J. Naish, and P. Bishop et al. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume Circ Cardiovasc Imaging 6 2013 373 383
77. M. Fontana, S.K. White, and S.M. Banypersad et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR J Cardiovasc Magn Reson 14 2012 88
78. A.S. Flett, D.M. Sado, and G. Quarta et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study Eur Heart J Cardiovasc Imaging 13 2012 819 826
79. S.K. White, D.M. Sado, and M. Fontana et al. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique J Am Coll Cardiol Img 6 2013 955 962
80. C.A. Beltrami, N. Finato, and M. Rocco et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans Circulation 89 1994 151 163
81. E.B. Schelbert, L.Y. Hsu, and S.A. Anderson et al. Late gadolinium-enhancement cardiac magnetic resonance identifies postinfarction myocardial fibrosis and the border zone at the near cellular level in ex vivo rat heart Circ Cardiovasc Imaging 3 2010 743 752
82. N. Kawel, M. Nacif, and A. Zavodni et al. T1 mapping of the myocardium: Intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region J Cardiovasc Magn Reson 14 2012 27
83. S. Liu, J. Han, and M.S. Nacif et al. Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials J Cardiovasc Magn Reson 14 2012 90
84. P. Kellman, and M.S. Hansen T1-mapping in the heart: accuracy and precision J Cardiovasc Magn Reson 16 2014 2
85. M.S. Nacif, N. Kawel, and J.J. Lee et al. Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT Radiology 264 2012 876 883
86. S. Bandula, S.K. White, and A.S. Flett et al. Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings Radiology 269 2013 396 403
87. C.S. Broberg, S.S. Chugh, C. Conklin, D.J. Sahn, and M. Jerosch-Herold Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease Circ Cardiovasc Imaging 3 2010 727 734
88. F.P. Mongeon, M. Jerosch-Herold, O.R. Coelho-Filho, R. Blankstein, R.H. Falk, and R.Y. Kwong Quantification of extracellular matrix expansion by CMR in infiltrative heart disease J Am Coll Cardiol Img 5 2012 897 907
89. J. Schaper, H. Mollnau, S. Hein, D. Scholz, B. Münkel, and B. Devaux Interactions between cardiomyocytes and extracellular matrix in the failing human heart Z Kardiol 84 1995 33 38
90. E.B. Schelbert, J.J. Cao, and S. Sigurdsson et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults JAMA 308 2012 890 896
91. T.C. Wong, K. Piehler, and K.S. Puntil et al. Effectiveness of late gadolinium enhancement to improve outcomes prediction in patients referred for cardiovascular magnetic resonance after echocardiography J Cardiovasc Magn Reson 15 2013 1
92. B.Y. Cheong, R. Muthupillai, and J.M. Wilson et al. Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction Circulation 120 2009 2069 2076
93. I. Klem, D.J. Shah, and R.D. White et al. Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage: an international, multicenter study Circ Cardiovasc Imaging 4 2011 610 619
94. R.J. Kim, E. Wu, and A. Rafael et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction N Engl J Med 343 2000 1445 1453
95. A. Gulati, A. Jabbour, and T.F. Ismail et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy JAMA 309 2013 896 908
96. S. de Waha, S. Desch, and I. Eitel et al. Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction: a comparison with traditional prognostic markers Eur Heart J 31 2010 2660 2668
97. T.C. Wong, K.M. Piehler, and K.M. Zareba et al. Myocardial damage detected by late gadolinium enhancement cardiovascular magnetic resonance is associated with subsequent hospitalization for heart failure J Am Heart Assoc 2 2013 e000416
98. S. Schalla, S.C. Bekkers, and R. Dennert et al. Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: comparison of magnetic resonance imaging with right ventricular biopsy Eur J Heart Fail 12 2010 227 231
99. A.S. Flett, J. Hasleton, and C. Cook et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance J Am Coll Cardiol Img 4 2011 150 156
100. R.Y. Kwong, and A. Farzaneh-Far Measuring myocardial scar by CMR J Am Coll Cardiol Img 4 2011 157 160
101. J.E. Ho, C. Liu, and A. Lyass et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J Am Coll Cardiol 60 2012 1249 1256
102. E. Barasch, J.S. Gottdiener, and G. Aurigemma et al. The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study Circ Heart Fail 4 2011 733 739
103. A.R. van der Velde, L. Gullestad, and T. Ueland et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH Circ Heart Failure 6 2013 219 226
104. R.A. de Boer, D.J. van Veldhuisen, and R.T. Gansevoort et al. The fibrosis marker galectin-3 and outcome in the general population J Intern Med 272 2012 55 64
105. H. Krum, M. Elsik, and H.G. Schneider et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy Circ Heart Fail 4 2011 561 568
106. N.C. Henderson, A.C. Mackinnon, and S.L. Farnworth et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis Proc Natl Acad Sci U S A 103 2006 5060 5065
107. D.K. Hsu, C.A. Dowling, K.C. Jeng, J.T. Chen, R.Y. Yang, and F.T. Liu Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma Int J Cancer 81 1999 519 526
108. Y. Nishi, H. Sano, and T. Kawashima et al. Role of galectin-3 in human pulmonary fibrosis Allergol Int 56 2007 57 65
109. M. Kubanek, M. Sramko, and J. Maluskova et al. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy J Am Coll Cardiol 61 2013 54 63
110. R.S. Velagaleti, P. Gona, and J. Sundstrom et al. Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality Arterioscler Thromb Vasc Biol 30 2010 2283 2288
111. N. Lopez-Andres, P. Rossignol, and W. Iraqi et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial Eur J Heart Fail 14 2012 74 81
112. P.J. Lijnen, T. Maharani, N. Finahari, and J.S. Prihadi Serum collagen markers and heart failure Cardiovasc Hematol Disord Drug Targets 12 2012 51 55
113. B. Lopez, R. Querejeta, and N. Varo et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients Circulation 104 2001 286 291
114. B. Pitt, G. Filippatos, and M. Gheorghiade et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease Eur J Heart Fail 14 2012 668 675
115. M. Metra, J.R. Teerlink, and G.M. Felker et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study Eur J Heart Fail 12 2010 1130 1139
116. E. van Rooij, and E.N. Olson MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles Nat Rev Drug Discov 11 2012 860 872
117. A.F. Hernandez, X. Mi, and B.G. Hammill et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction JAMA 308 2012 2097 2107
118. A. Zanchi, M. Maillard, and M. Burnier Recent clinical trials with omapatrilat: new developments Curr Hypertens Rep 5 2003 346 352
119. D.L. Mann, B. Bozkurt, G. Torre-Amione, O.Z. Soran, and N. Sivasubramanian Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability Clin Transl Sci 1 2008 142 145
120. A.M. Feldman TNF alpha-still a therapeutic target Clin Transl Sci 1 2008 145
121. T. Thum, and J.M. Lorenzen Cardiac fibrosis revisited by microRNA therapeutics Circulation 126 2012 800 802
122. T.A. Wynn Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases J Clin Invest 117 2007 524 529
123. A. Leask Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation Circ Res 106 2010 1675 1680
124. R.F. Duisters, A.J. Tijsen, and B. Schroen et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling Circ Res 104 2009 170 178
125. J.C. Moon, E. Reed, and M.N. Sheppard et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy J Am Coll Cardiol 43 2004 2260 2264
126. K.R. Anderson, M.G. Sutton, and J.T. Lie Histopathological types of cardiac fibrosis in myocardial disease J Pathol 128 1979 79 85
127. N. Hu, X. Han, E.K. Lane, F. Gao, Y. Zhang, and J. Ren Cardiac-specific overexpression of metallothionein rescues against cigarette smoking exposure-induced myocardial contractile and mitochondrial damage PLoS One 8 2013 e57151
128. G. Rajiyah, R. Agarwal, G. Avendano, M. Lyons, B. Soni, and T.J. Regan Influence of nicotine on myocardial stiffness and fibrosis during chronic ethanol use Alcohol Clin Exp Res 20 1996 985 989
129. S.S. Ahmed, C.B. Moschos, M.M. Lyons, H.A. Oldewurtel, R.J. Coumbis, and T.J. Regan Cardiovascular effects of long-term cigarette smoking and nicotine administration Am J Cardiol 37 1976 33 40
130. L.J. Steinherz, P.G. Steinherz, C.T. Tan, G. Heller, and M.L. Murphy Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 266 1991 1672 1677
131. J.A. Roldao, M. Beghini, and L.S. Ramalho et al. Comparison between the collagen intensity and mast cell density in the lingual muscles and myocardium of autopsied chronic chagasic and nonchagasic patients Parasitol Res 111 2012 647 654
132. S.V. Babu-Narayan, K.P. McCarthy, S.Y. Ho, A.G. Magee, P.J. Kilner, and M.N. Sheppard Images in cardiovascular medicine. Myocarditis and sudden cardiac death in the young: extensive fibrosis suggested by cardiovascular magnetic resonance in vivo and confirmed post mortem Circulation 116 2007 e122 e125
133. P. Lurz, I. Eitel, and J. Adam et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis J Am Coll Cardiol Img 5 2012 513 524
134. M.R. Patel, P.J. Cawley, and J.F. Heitner et al. Detection of myocardial damage in patients with sarcoidosis Circulation 120 2009 1969 1977
135. K.J. Silverman, G.M. Hutchins, and B.H. Bulkley Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis Circulation 58 1978 1204 1211
136. K. Watanabe, V. Sukumaran, and P.T. Veeraveedu et al. Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis Inflamm Allergy Drug Targets 10 2011 218 225
137. M. Pichler, P.P. Rainer, S. Schauer, and G. Hoefler Cardiac fibrosis in human transplanted hearts is mainly driven by cells of intracardiac origin J Am Coll Cardiol 59 2012 1008 1016
138. A. Ansari, C.J. Kaupke, N.D. Vaziri, R. Miller, and A. Barbari Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis Int J Artif Organs 16 1993 31 36
139. H.P. Krayenbuehl, O.M. Hess, E.S. Monrad, J. Schneider, G. Mall, and M. Turina Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement Circulation 79 1989 744 755